Welcome to our dedicated page for Ingevity Corporation news (Ticker: $NGVT), a resource for investors and traders seeking the latest updates and insights on Ingevity Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ingevity Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ingevity Corporation's position in the market.
Ingevity (NYSE: NGVT) reported a decline in first quarter 2024 net sales of $340.1 million, down 13% primarily due to the repositioning of the Performance Chemicals segment. The company incurred a net loss of $56.0 million with diluted loss per share of $1.54, offset by adjusted earnings of $19.1 million and diluted adjusted EPS of $0.52. Ingevity realized cost savings of $20 million in Q1 and aims for $65-75 million in 2024. Full-year guidance includes sales of $1.40-$1.55 billion and adjusted EBITDA between $365-$390 million.
